Fiche publication
Date publication
décembre 2019
Journal
Biomolecules
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
,
Dr REBE Cédric
Tous les auteurs :
Rébé C, Demontoux L, Pilot T, Ghiringhelli F
Lien Pubmed
Résumé
Along with surgery and radiotherapy, chemotherapeutic agents belong to the therapeutic arsenal in cancer treatment. In addition to their direct cytotoxic effects, these agents also impact the host immune system, which might enhance or counteract their antitumor activity. The platinum derivative compounds family, mainly composed of carboplatin, cisplatin and oxaliplatin, belongs to the chemotherapeutical arsenal used in numerous cancer types. Here, we will focus on the effects of these molecules on antitumor immune response. These compounds can induce or not immunogenic cell death (ICD), and some strategies have been found to induce or further enhance it. They also regulate immune cells' fate. Platinum derivatives can lead to their activation. Additionally, they can also dampen immune cells by selective killing or inhibiting their activity, particularly by modulating immune checkpoints' expression.
Mots clés
carboplatin, cisplatin, immune checkpoints, immunogenic cell death, oxaliplatin
Référence
Biomolecules. 2019 Dec 20;10(1):
